Literature DB >> 23979740

Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits.

Nina V Malkevich1, Subhendu Basu, Thomas L Rudge, Kristin H Clement, Ajoy C Chakrabarti, Ronald T Aimes, Gary S Nabors, Mario H Skiadopoulos, Boris Ionin.   

Abstract

Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that contains neutralizing antibodies against protective antigen (PA), a component of anthrax toxins. We evaluated the interaction between AIGIV and BioThrax (anthrax vaccine adsorbed) in rabbits. While pharmacokinetics of AIGIV were not altered by vaccination, the vaccine-induced immune response was abrogated in AIGIV-treated animals.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23979740      PMCID： PMC3811249          DOI： 10.1128/AAC.00460-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Regulation of VH gene repertoire and somatic mutation in germinal centre B cells by passively administered antibody.

Authors:  H Song; X Nie; S Basu; M Singh; J Cerny
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

2.  Response to trivalent oral poliovirus vaccine with and without immune serum globulin in young adults in Israel in 1988.

Authors:  M S Green; J L Melnick; D Cohen; R Slepon; Y L Danon
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

3.  Specific suppression of immune responses.

Authors:  D A Rowley; F W Fitch; F P Stuart; H Köhler; H Cosenza
Journal:  Science       Date:  1973-09-21       Impact factor: 47.728

4.  Passive-active immunisation against hepatitis B: immunogenicity studies in adult Americans.

Authors:  W Szmuness; C E Stevens; W R Oleszko; A Goodman
Journal:  Lancet       Date:  1981-03-14       Impact factor: 79.321

5.  Does immunoglobulin interfere with the immunogenicity to Pasteur Mérieux inactivated hepatitis A vaccine?

Authors:  A Zanetti; F Pregliasco; A Andreassi; A Pozzi; P Viganò; A Cargnel; P Briantais; E Vidor
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

6.  Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine? A comparative clinical trial in adults.

Authors:  R Dal-Ré; A Gil; A González; L Lasheras
Journal:  J Clin Pharmacol       Date:  1995-04       Impact factor: 3.126

Review 7.  Anthrax as a biological weapon, 2002: updated recommendations for management.

Authors:  Thomas V Inglesby; Tara O'Toole; Donald A Henderson; John G Bartlett; Michael S Ascher; Edward Eitzen; Arthur M Friedlander; Julie Gerberding; Jerome Hauer; James Hughes; Joseph McDade; Michael T Osterholm; Gerald Parker; Trish M Perl; Philip K Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

8.  Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.

Authors:  David Kobiler; Yehoshua Gozes; Hagai Rosenberg; Dino Marcus; Shaul Reuveny; Zeev Altboum
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

9.  In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Authors:  M L Pitt; S F Little; B E Ivins; P Fellows; J Barth; J Hewetson; P Gibbs; M Dertzbaugh; A M Friedlander
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

10.  Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979.

Authors:  F A Abramova; L M Grinberg; O V Yampolskaya; D H Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205
View more
  6 in total

1.  Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.

Authors:  David Bussing; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-09-02       Impact factor: 2.745

Review 2.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

3.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

4.  Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.

Authors:  Nutan Mytle; Robert J Hopkins; Nina V Malkevich; Subhendu Basu; Gabriel T Meister; Daniel C Sanford; Jason E Comer; Kristopher E Van Zandt; Mohamed Al-Ibrahim; William G Kramer; Cris Howard; Nancy Daczkowski; Ajoy C Chakrabarti; Boris Ionin; Gary S Nabors; Mario H Skiadopoulos
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

5.  First vaccine approval under the FDA Animal Rule.

Authors:  David W C Beasley; Trevor L Brasel; Jason E Comer
Journal:  NPJ Vaccines       Date:  2016-08-25       Impact factor: 7.344

6.  Expression, Purification, and Biophysical Characterization of a Secreted Anthrax Decoy Fusion Protein in Nicotiana benthamiana.

Authors:  Kalimuthu Karuppanan; Sifti Duhra-Gill; Muchena J Kailemia; My L Phu; Carlito B Lebrilla; Abhaya M Dandekar; Raymond L Rodriguez; Somen Nandi; Karen A McDonald
Journal:  Int J Mol Sci       Date:  2017-01-04       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.